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Abstract
Background: Cases of recurrent inflammatory pseudotumor have only rarely been reported. The treatment for
recurrent pseudotumor is surgery. Patients not eligible for surgery require different treatment, and the optimal type
of the treatment is controversial.
Case Presentation: A 54-year-old woman was noted to have an abnormal shadow in the right middle lung field on
c h e s tX - r a y .C o m p u t e dt o m o g r a p h yo ft h ec h e s tr e v e a l e da ni nfiltrative lesion in the right segment 4 and a nodule in the
right segment 8. She underwent right middle lobectomy and partial resection of the right segment 8. Histopathology
revealed non-atypical lymphocytes and plasma cells infiltrates, leading to the diagnosis of the lymphoplasmacytic type of
inflammatory pseudotumor. During postoperative follow-up, chest computed tomography revealed a nodular lesion in
the left segment 3 and an infiltrative lesion in the right segment 2. Left segment 3 segmentectomy and right segment 2
wedge resection were performed. The histopathological findings were similar to those of the first surgical specimen,
leading to the diagnosis of recurrent lymphoplasmacytic type of inflammatory pseudotumor.
Conclusion: Surgical cases of recurrent inflammatory pseudotumor of the lung have been reported only very
rarely. We believe that surgery is the best treatment for recurrent inflammatory pseudotumor of the lung when
patients are eligible.
Background
Inflammatory pseudotumor is a rare disease of unknown
etiology. The histopathological correlates include a spec-
trum of fibroblastic or myofibroblastic proliferation with a
varying infiltrate of inflammatory cells, including plasma
cells, lymphocytes and histiocytes. Inflammatory pseudotu-
mor of the lung is generally treated surgically, and the
prognosis of patients undergoing complete surgical resec-
tion is favorable [1-7]. However, patients with recurrent
inflammatory pseudotumor of the lung have rarely been
reported and no effective treatment for such disease has
been established. Here, we present a surgically treated case
of intrapulmonary recurrence of inflammatory pseudotu-
mor of the lung.
Case Presentation
The patient was a 54-year-old woman with a history of 8
pack years of cigarette smoking. Her past medical history
was unremarkable. During a medical check-up, a shadow
in the right middle lung field was found on chest X-ray
(Figure 1A). She was referred to our department for com-
puted tomography (CT) of the chest, which revealed a
30-mm infiltrative lesion in the right segment 4 (S4) and
a 6-mm nodule in the right S8 (Figure 2A). Blood sam-
ples did not exhibit any abnormalities, including serum
immunoglobulin G4 (IgG4), and the tumor markers NSE,
CEA, SCC and SLX were within normal limits. As
bronchoscopy was nondiagnostic, right middle lobectomy
and partial resection of the right S8 were performed. His-
topathology showed non-atypical lymphocytes and
plasma cells infiltrates, which together had formed lymph
follicles with germinal centers (Figure 3A-C). Immunos-
taining showed that CD20-positive B cells were present
in the germinal center, and CD3-positive T cells were
observed around them, thus displaying a normal cell dis-
tribution. The B cells in the germinal center were positive
for CD10, but negative for bcl-2, excluding the possibility
of lymphoma. Infiltrates comprised of collagen fibers and
damaged alveolar elastic fibers were found (Figure 3B).
Lymphocytic infiltration of the vascular walls was present
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for immunoglobulin G, immunoglobulin M, immunoglo-
bulin A, the kappa light chain or lambda light chain
observed in antibody-producing cells, with no evidence
of monoclonal proliferation of B cells or plasma cells. No
increase was observed in the number of IgG4-positive
plasma cells. Both the S4 and S8 tumor yielded patholo-
gical findings similar to the sort described above, and this
Figure 1 Chest X-rays taken before the first (A) and second (B) operation. (A) Chest X-ray shows an ill-defined consolidative lesion in the
right middle lung field. (B) Chest X-ray shows an ill-defined consolidative lesion in the left middle lung field. The arrows indicate the lesions.
Figure 2 CT and PET/CT performed before the first (A) and second (B, C) surgery. A, A 30-mm infiltrative lesion and a 6-mm nodule are
seen in the right S4 and S8, respectively. B, An 18-mm nodular lesion and a 16-mm infiltrative lesion are seen in the left S3 and right S2,
respectively. C, PET/CT shows fluorodeoxyglucose uptake within these lesions. The arrows indicate the lesions.
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inflammatory pseudotumor.
On 4 year postoperative follow-up, chest X-ray revealed
a nodular lesion in the left middle lung field (Figure 1B).
Chest CT revealed an 18-mm nodular lesion in the left S3
and a 16-mm infiltrative lesion in the right S2 (Figure 2B).
Bronchoscopy was nondiagnotic once again. Positron
emission tomography (PET)/CT showed maximum stan-
dardized uptake values of 2.7 and 3.2 in the masses in the
left S3 and right S2, respectively (Figure 2C). These were
high fluorodeoxyglucose uptake lesions with maximum
standardized uptake values ≥2.5, and, considering the
shape of the tumors, either primary lung cancer or recur-
rence of the inflammatory pseudotumor was suspected.
It was critically important to differentiate inflammatory
pseudotumor from lung cancer, and, even when a
determination of recurrent inflammatory pseudotumors
was made, resection was indicated in an effort to achieve
long-term survival. Therefore, left S3 segmentectomy was
performed at first. The histopathology findings were simi-
lar to those of the surgical specimens obtained in the first
operation (Figure 4A-D), therefore recurrence of the lym-
phoplasmacytic type of inflammatory pseudotumor was
diagnosed. At this point, the residual right S2 lesion was
also considered to be a recurrent inflammatory pseudotu-
mor, but the patient did not wish to receive non-surgical
treatment. Since the patient planned to move immediately
before surgery, video-assisted thoracoscopic wedge resec-
tion of right S2 was performed at another hospital, and
the same type of inflammatory pseudotumor was diag-
nosed histopathologically. Currently, 18 months after the
last lung surgery, the patient remains free of disease.
Figure 3 Histopathology of the first surgical specimen. A, Lymphoid hyperplasia with germinal centers and exudative changes. B,
Proliferation of collagen fibers and destruction of alveolar elastic fibers (left, hematoxylin and eosin staining; right, Elastica-van Gieson staining).
C, Infiltrating lymphocytes and plasma cells without atypia. D, Lymphocytic infiltration of vascular walls (left, hematoxylin and eosin staining;
right, Elastica-van Gieson staining).
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Inflammatory pseudotumor is comprised of a variable mix
of inflammatory and mesenchymal cells, including plasma
cells, histiocytes, lymphocytes and fibroblasts. Inflamma-
tory pseudotumor usually arises within the lung, although
it may also occur at many other sites [8]. Most of the
reported cases were in patients younger than 40 years of
age, with a mean age of 27 - 50 years [9]. Both genders are
equally affected. No special geographic or ethnic predomi-
nance has been reported. The incidence of this lesion in
the lung is between 0.04 and 1.0% in the general popula-
tion [10-13]. Whether an inflammatory pseudotumor is a
reactive lesion or a spontaneous neoplasm is controversial,
and the precise etiology at present is still unknown. An
IgG4-related immunopathological process has attracted
attention as a cause of inflammatory pseudotumor in
recent years [14]; however, in this patient, the serum IgG4
level was in the normal range, and the IgG4-positive
plasma cells in the tumor were immunohistochemically
few in number, excluding any association with IgG4-
related sclerosing disease. Approximately half of these
patients do not exhibit clinical symptoms, and the lesions
are often detected incidentally on chest radiographs, while
26-56% of patients have been reported to show clinical
symptoms, such as cough, hemosputum, dyspnea and
chest pain [13].
The radiological features of inflammatory pseudotumors
of the lung have been analyzed by Agrons et al. [9]. Chest
CT reportedly reveals a single nodule or mass in approxi-
mately 90% of these patients, with multiple nodules in 5%
[9]. Secondary infiltration of the hilum, mediastinum and
airways is apparent in 16% of patients [9]. PET/CT is
usually positive, as in the present case [15]. It is often diffi-
cult to make the diagnosis of inflammatory pseudotumor
on preoperative imaging findings alone, as there is a highly
complex differential diagnosis. Histology specimen
obtained by bronchoscopic biopsy or transthoracic fine-
needle aspiration are often equivocal. Hence, surgery, such
as video-assisted thoracic resection or open lung biopsy, is
often required [10,16].
Matsubara et al. categorized three types of inflamma-
tory pseudotumor based on the predominant cell types
Figure 4 Histopathology of the second surgical specimen. A, A nodular lesion well circumscribed by interlobular septa. Lymphoid
hyperplasia with germinal centers and exudative changes (left, hematoxylin and eosin staining; right, Elastica-van Gieson staining). B, Proliferation
of collagen fibers and destruction of alveolar elastic fibers (left, hematoxylin and eosin staining; right, Elastica-van Gieson staining). C, Infiltrating
lymphocytes and plasma cells without atypia. D, Lymphocytic infiltration of vascular walls (left, hematoxylin and eosin staining; right, Elastica-van
Gieson staining).
Goto et al. World Journal of Surgical Oncology 2011, 9:133
http://www.wjso.com/content/9/1/133
Page 4 of 6and main histological characteristics [13]: (i) an organiz-
ing pneumonia type with gradual resolution of intra-
alveolar exudates; (ii) a fibrous histiocytoma type with
storiform proliferation of plasmacyte and lymphocyte
aggregations; and (iii) a lymphoplasmacytic type with
aggregation of both plasmacytes and lymphocytes, as in
the case reported here.
The treatment of choice for pulmonary inflammatory
pseudotumor is surgery [1-7]. Inflammatory pseudotu-
mors of the lung usually do not recur after complete
resection [3,5]. The prognosis of patients who undergo
radical resection is excellent [1-7]. Nevertheless, relapse
can occur even many years after resection [6,17], and dis-
ease-related deaths have been reported [6,10,18]. In a
comparably large series of 23 surgically treated cases over
47 years, only three recurrences were reported, all due to
incomplete resection [10]. Two have had subsequent
complete excision of enlarged residual tumors with no
evidence of recurrence 8 and 9 years later [10]. To our
knowledge, this paper is the first report on the surgical
resection of metachronous lesions in different parts of
the lung, rather than residual tumor growth.
According to Cerfolio et al., patients with recurrent
d i s e a s ew h oa r es u i t a b l ef o rs u r g e r ys h o u l du n d e r g o
reresection [10]. Their long-term follow-up documented
that complete resection leads to extended disease-free
intervals. In our case, left S3 segmentectomy and right
S2 wedge resection were performed for the purposes of
both diagnosis and treatment. We selected surgery
because (i) it was necessary to differentiate inflammatory
pseudotumor from lung cancer, (ii) even if it was a
recurrent inflammatory pseudotumor, there were only
two lesions in the lung, and their resection was expected
to afford long-term survival, and (iii) the patient did not
wish to receive prolonged non-surgical treatment. It is
reported that radiotherapy and steroids have each been
employed for anatomically and functionally inoperable
patients, and also in patients with recurrent disease
[19-22]. However, the results of those treatments are
widely variable, ranging from ineffective to complete
regression [10,20,22]. A larger number of long-term fol-
low-up cases will be needed to establish a clear treat-
ment algorithm.
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